SPARC, the R&D arm of Sun Pharma, was testing SCD-044 for two auto-immune indications in a Phase-2 trial. Though the study did not show any safety concerns, the drug failed the endpoint of a 75 per cent improvement in PASI score and EASI score at week 16
